Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2023 |
|---|---|
| Revenue | — |
| R&D expense | $6.5M |
| Operating income | −$10.3M |
| Net income | −$8.4M |
| Cash & equivalents | $10.5M |
| Total debt | — |
| Operating cash flow | −$8.2M |
| Free cash flow | −$8.3M |
Company profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an investigative formulation of inhaled interferon beta (IFN-ß') for the treatment and prevention of severe viral lung infections in high-risk patient groups. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.